Premium
Complete and long‐lasting cytologic and molecular remission of FIP 1L1‐ PDGFRA ‐ positive acute eosinophil myeloid leukaemia, treated with low‐dose imatinib monotherapy
Author(s) -
Barraco Daniela,
Carobolante Francesca,
Candoni Anna,
Simeone Erica,
Piccaluga Pierpaolo,
Tabanelli Valentina,
Fanin Renato
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12272
Subject(s) - eosinophil , imatinib , myeloid leukaemia , pdgfra , myeloid , medicine , immunology , chronic myeloid leukaemia , eosinophilia , myeloid leukemia , gist , cancer research , stromal cell , asthma
Myeloproliferative neoplasms associated with FIP 1L1‐ PDGFR rearrangements represent a rare subset of myeloid and lymphoid malignancies, characterised by the presence of eosinophilia and abnormalities of PDGFRA , PDGFRB or FGFR 1 genes. The fusion product of such genes is a tyrosine kinase oncoprotein sensitive to imatinib, which to date results to be the standard of care for FIP 1L1‐ PDGFRA ‐ positive chronic myeloproliferative disorders with eosinophilia. However, the coexistence of FIP 1L1‐ PDGFRA rearrangement associated with acute myeloid leukaemia is extremely rare. Here, we report a rare case of FIP 1L1‐ PDGFRA ‐ positive acute myeloid leukaemia, with marked peripheral blood and bone marrow eosinophilia, treated with low dose of imatinib monotherapy, achieving a rapid and long‐lasting complete cytologic and molecular remission, without need for intensive chemotherapy.